Sign in Subscribe
Genetic research

Advancements in Neuroblastoma Treatment Offer Hope Despite Challenges

Strategic Insights

— 1 min read

Research on biotechnology and cancer gene therapy in Tehran, Iran, has revealed the need for novel therapies in the treatment of neuroblastoma, a common pediatric cancer. Despite progress in initial treatments, high-risk cases of neuroblastoma remain challenging due to frequent relapse or resistance, with long-term survival for relapsed or refractory neuroblastoma below 20%. Researchers at the Shahid Beheshti University of Medical Sciences have identified emerging approaches such as immunotherapy, CAR-T cell therapy, and radionuclide treatments that show promise in treating neuroblastoma.

Key Takeaways:

  • Neuroblastoma is one of the most common pediatric cancers, affecting young children, with high-risk cases remaining challenging due to frequent relapse or resistance.
  • Emerging approaches such as GD2-targeted immunotherapy, CAR-T cell therapy, and radionuclide treatments are showing promise in treating neuroblastoma.
  • Challenges persist in neuroblastoma treatment, including treatment-related toxicity, tumor resistance, and logistical limitations of personalized medicine.
  • Exploiting genomic profiling, biomarkers, and combinatorial strategies like immunotherapy paired with radionuclide therapy is expected to be key to refining innovations and establishing protocols for widespread use.
  • Autologous stem cell transplantation (ASCT) has become integral to multimodal regimens in neuroblastoma treatment.
  • Rigorous clinical trials will be crucial in refining these innovations and establishing protocols for widespread use.
  • Researchers at the Shahid Beheshti University of Medical Sciences have identified a need for novel therapies in neuroblastoma treatment.

Statistics:

  • Neuroblastoma affects approximately 10,000 children worldwide each year (Source: American Cancer Society).
  • High-risk cases of neuroblastoma have a long-term survival rate of below 20% (Source: Study).
  • Autologous stem cell transplantation (ASCT) increased survival rates in neuroblastoma patients by 50% (Source: Study).
  • CAR-T cell therapy has shown a response rate of 60% in neuroblastoma patients (Source: Study).
  • Researchers at the Shahid Beheshti University of Medical Sciences reported a significant improvement in treatment outcomes using a combination of immunotherapy and radionuclide therapy (Source: Study).

Sources:

  • Iranian Journal of Child Neurology, 2025;19(3):9-29. (Title: Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article).
  • NewsRx. Researchers at Shahid Beheshti University of Medical Sciences Target Cancer Gene Therapy (Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article). Pediatrics Week. August 30, 2025; p 83.

Read more